PRESIDENT AND CEO Williamson Steven S. sold $197,699 worth of shares (27,689 units at $7.14) and was granted 181,696 shares, increasing direct ownership by 69% to 376,038 units (SEC Form 4)

$LUNG
Medical/Dental Instruments
Health Care
Get the next $LUNG alert in real time by email
SEC FORM 4 SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
  
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Williamson Steven S.

(Last) (First) (Middle)
C/O PULMONX CORPORATION
700 CHESAPEAKE DRIVE

(Street)
REDWOOD CITY CA 94063

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Pulmonx Corp [ LUNG ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
PRESIDENT AND CEO
3. Date of Earliest Transaction (Month/Day/Year)
03/03/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 03/03/2025 S(1) 27,689 D $7.14 194,342(2) D
Common Stock 03/03/2025 A 181,696(3) A $0 376,038 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Option (right to buy) $8.29 03/03/2025 A 128,395 (4) 03/02/2035 Common Stock 128,395 $0 128,395 D
Explanation of Responses:
1. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units (the "RSUs") granted on March 15, 2024.
2. Includes 2,500 shares acquired by the reporting person under the Issuer's 2020 Employee Stock Purchase Plan on February 21, 2025.
3. Represents grant of RSUs payable solely in common stock of the Issuer that vest in equal quarterly installments over the four-year period from the grant date of March 3, 2025.
4. The shares subject to the option vest in 48 equal monthly installments from the grant date on March 3, 2025.
/s/ David Aaron Lehman, Attorney-in-Fact 03/05/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Get the next $LUNG alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$LUNG

DatePrice TargetRatingAnalyst
3/10/2025$17.00Buy
D. Boral Capital
12/11/2024$17.00 → $7.50Buy → Neutral
Citigroup
6/4/2024$12.00Buy
Lake Street
2/23/2024$16.00 → $14.00Overweight → Equal Weight
Wells Fargo
9/5/2023$18.00Buy
Craig Hallum
2/27/2023$10.00 → $15.00Equal Weight → Overweight
Wells Fargo
1/3/2023$8.00Neutral → Underperform
BofA Securities
12/12/2022$14.00 → $10.00Neutral → Buy
Citigroup
More analyst ratings

$LUNG
Press Releases

Fastest customizable press release news feed in the world

See more
  • EDAP Appoints Glen French to Board of Directors

    PDF Version LYON, France, March 3, 2025 -- EDAP TMS SA (NASDAQ:EDAP) ("the Company" or "EDAP"), the global leader in robotic energy-based therapies, today announced the appointment of Glen French to its Board of Directors.          "We are pleased to welcome Glen to our Board of Directors," said Dr. Lance Willsey, Interim Chairman of the Board of EDAP TMS. "Glen is a highly accomplished executive with extensive business and clinical expertise in the development of innovative new medical devices and technology, and his presence on our Board of Directors will help guide our strategic decision-making as we establish Focal One as the world's premier robotic HIFU technology platform."        

    $EDAP
    $LUNG
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Medical/Dental Instruments
  • Pulmonx Reports Record Fourth Quarter and Full Year 2024 Financial Results

    REDWOOD CITY, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the fourth quarter and full year ended December 31, 2024. Recent Highlights Delivered $83.8 million in worldwide revenue for the full year of 2024, a 22% increase over the prior yearAchieved record worldwide revenue of $23.8 million for the fourth quarter of 2024, a 23% increase over the same period last year on an as reported and constant currency basisSet a record of $15.9 million and $56.5 million in U.S. revenue for the fourth quarter 2024 and the full year 20

    $LUNG
    Medical/Dental Instruments
    Health Care
  • Pulmonx to Present at the Citi 2025 Unplugged Medtech and Life Sciences Access Day

    REDWOOD CITY, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx") a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the Citi 2025 Unplugged Medtech and Life Sciences Access Day in New York on Thursday, February 27, 2025, at 8:00 AM PT / 11:00 AM ET. A live and archived webcast of the presentation will be available on "Investors" section of the Pulmonx website at https://investors.pulmonx.com/. About Pulmonx CorporationPulmonx Corporation (NASDAQ:LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmon

    $LUNG
    Medical/Dental Instruments
    Health Care

$LUNG
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$LUNG
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$LUNG
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$LUNG
SEC Filings

See more

$LUNG
Leadership Updates

Live Leadership Updates

See more
  • Pulmonx Announces Appointment of Mehul Joshi as Chief Financial Officer

    REDWOOD CITY, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced the appointment of Mehul Joshi as Chief Financial Officer, effective April 3, 2024. He succeeds John McKune, who has served as the Company's Interim Chief Financial Officer since October 10, 2023, and will transition to his prior role as Vice President, Corporate Controller. "Mehul is an exceptionally accomplished financial executive and I am excited to welcome him to our leadership team. His proven track record of leading global finance teams within large, diversified companies makes him

    $LUNG
    Medical/Dental Instruments
    Health Care
  • Pulmonx Announces Retirement of CEO Glen French and Appointment of Industry Veteran Steve Williamson as President and Chief Executive Officer

    REDWOOD CITY, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced that Glen French will retire as the Company's President and Chief Executive Officer, effective March 15, 2024, following over nine years of service to Pulmonx. Concurrently, the Company announced the appointment of Steve Williamson as President and Chief Executive Officer, and as a member of the Company's Board of Directors, also effective March 15, 2024. Mr. French will serve as a Senior Advisor to Mr. Williamson until May 1, 2024 to ensure a seamless transition and then remain a member of

    $LUNG
    Medical/Dental Instruments
    Health Care
  • The Honest Company Announces Appointment of Michael Barkley, Alissa Hsu Lynch, and Andrea Turner to the Board of Directors

    LOS ANGELES, Dec. 11, 2023 (GLOBE NEWSWIRE) -- The Honest Company (NASDAQ:HNST), a digitally-native consumer products company dedicated to creating clean- and sustainably-designed products spanning baby care, beauty, personal care, wellness and household care, today announced that Michael Barkley, Former Chief Executive Officer of Kind LLC, Alissa Hsu Lynch, Former Global Head of MedTech Strategy and Solutions for Google Cloud, and Andrea Turner, Former Senior Vice President, Global Customer Service & Logistics at Mondelēz International, Inc., have been appointed to its Board of Directors effective December 8, 2023. "We are pleased to welcome Michael, Alissa and Andrea to our board of dir

    $HNST
    $LUNG
    Catalog/Specialty Distribution
    Consumer Discretionary
    Medical/Dental Instruments
    Health Care

$LUNG
Financials

Live finance-specific insights

See more
  • Pulmonx Reports Record Fourth Quarter and Full Year 2024 Financial Results

    REDWOOD CITY, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the fourth quarter and full year ended December 31, 2024. Recent Highlights Delivered $83.8 million in worldwide revenue for the full year of 2024, a 22% increase over the prior yearAchieved record worldwide revenue of $23.8 million for the fourth quarter of 2024, a 23% increase over the same period last year on an as reported and constant currency basisSet a record of $15.9 million and $56.5 million in U.S. revenue for the fourth quarter 2024 and the full year 20

    $LUNG
    Medical/Dental Instruments
    Health Care
  • Pulmonx to Report Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025

    REDWOOD CITY, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx"), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the fourth quarter and full year of 2024 after the close of trading on Wednesday, February 19, 2025. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast of the event will be available on the "Investors" section of the Pulmonx website at https://investors.pulmonx.com/. About Pulmonx CorporationPulmonx Corporation (NASDAQ:LUNG) is a global leader in minimally invasive trea

    $LUNG
    Medical/Dental Instruments
    Health Care
  • Pulmonx Reports Third Quarter 2024 Financial Results

    REDWOOD CITY, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the third quarter of 2024 ended September 30, 2024. Recent Highlights Achieved worldwide revenue of $20.4 million in the third quarter of 2024, a 15% increase over the same period last yearDelivered $13.8 million in U.S. revenue in the third quarter of 2024, representing 17% year-over-year growthRealized gross margin of 74% in the third quarter of 2024Added 15 new Zephyr® Valve U.S. treatment centers in the third quarter of 20246-month data from the AeriSeal® CONV

    $LUNG
    Medical/Dental Instruments
    Health Care

$LUNG
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more